Serum zonulin is elevated in women with polycystic ovary syndrome and correlates with insulin resistance and severity of anovulation

European Journal of Endocrinology

Volumn 172, Issue 1, 2015, Pages 29-36

  Zhang, Dongmei ^a   Zhang, Li ^a   Yue, Fangzhi ^a   Zheng, Yingying ^a   Russell, Ryan ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PROLACTIN; TESTOSTERONE; UNCLASSIFIED DRUG; ZONULIN; CHOLERA TOXIN;

ADULT; ANOVULATION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GYNECOLOGICAL EXAMINATION; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY INDEX; INTESTINE MUCOSA PERMEABILITY; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PROTEIN BLOOD LEVEL; SCORING SYSTEM; BLOOD; CASE CONTROL STUDY; PHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; ANOVULATION; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHOLERA TOXIN; FEMALE; HUMANS; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84920449788     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0589     Document Type: Article

References (36)

1. Azziz R, Carmina E, Dewailly D., Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W., Janssen OE, Legro RS, Norman RJ, Taylor AE et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertility and Sterility 2009 91 456-488. (doi:10.1016/j.fertnstert.2008.06.035)
2. Vrbikova J, Grimmichova T, Dvorakova K., Hill M, Stanicka S & Vondra K. Family history of diabetes mellitus determines insulin sensitivity and b cell function in polycystic ovary syndrome. Physiological Research 2008 57 547-553. (doi: 10.1080/09513590902972133)
3. Tremellen K & Pearce K. Dysbiosis of gut microbiota (DOGMA) - a novel theory for the development of polycystic ovarian syndrome. Medical Hypotheses 2012 79 104-112. (doi:10.1016/j.mehy.2012.04.016)
4. Cani PD, Bibiloni R, Knauf C., Waget A, Neyrinck AM, Delzenne NM & Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008 57 1470-1481. (doi:10.2337/db07-1403)
5. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009 58 1091-1103. (doi:10.1136/gut.2008.165886)
6. Gummesson A, Carlsson LM, Storlien L.H., Backhed F., Lundin P, Lofgren L, Stenlof K., Lam YY, Fagerberg B & Carlsson B. Intestinal permeability is associated with visceral adiposity in healthy women. Obesity 2011 19 2280-2282. (doi:10.1038/oby.2011.251)
7. Piche T, Barbara G, Aubert P., Bruley des Varannes S, Dainese R, Nano JL, Cremon C, Stanghellini V, De Giorgio R, Galmiche JP et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009 58 196-201. (doi:10.1136/gut.2007.140806)
8. Maes M, Twisk FN, Kubera M & Ringel K. Evidence for inflammation and activation of cell-mediated immunity in myalgic encephalomye-litis/chronic fatigue syndrome (ME/CFS): increased interleukin-1, tumor necrosis factor-α, PMN-elastase, lysozyme and neopterin. Journal of Affective Disorders 2012 136 933-939. (doi:10.1016/j.jad.2011. 09.004)
9. Mathur R, Ko A, Hwang L.J., Low K., Azziz R & Pimentel M. Polycystic ovary syndrome is associated with an increased prevalence of irritable bowel syndrome. Digestive Diseases and Sciences 2010 55 1085-1089. (doi:10.1007/s10620-009-0890-5)
10. Harlow BL, Signorello LB, Hall J.E., Dailey C & Komaroff AL. Reproductive correlates of chronic fatigue syndrome. American Journal of Medicine 1998 105 94S-99S. (doi:10.1016/S0002-9343(98)00173-9)
11. Moghetti P, Tosi F, Bonin C., Di Sarra D, Fiers T, Kaufman J.M., Giagulli VA, Signori C, Zambotti F, Dall'Alda M et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2013 98 E628-E637. (doi:10.1210/jc.2012-3908)
12. de Kort S., Keszthelyi D & Masclee AA. Leaky gut and diabetes mellitus: what is the link? Obesity Reviews 2011 12 449-458. (doi:10.1111/j.1467-789X.2010.00845.x)
13. Fasano A. Zonulin, regulation of tight junctions, and autoimmune diseases. Annals of the New York Academy of Sciences 2012 1258 25-33. (doi:10.1111/j.1749-6632.2012.06538.x)
14. Wang W, Uzzau S, Goldblum SE & Fasano A. Human zonulin, a potential modulator of intestinal tight junctions. Journal of Cell Science 2000 113 4435-4440.
15. Sapone A, de Magistris L, Pietzak M, Clemente M.G., Tripathi A., Cucca F, Lampis R, Kryszak D., Carteni M, Generoso M et al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 2006 55 1443-1449. (doi:10.2337/db05-1593)
16. Smecuol E, Sugai E, Niveloni S., Vazquez H, Pedreira S, Mazure R., Moreno ML, Label M, Maurino E, Fasano A et al. Permeability, zonulin production, and enteropathy in dermatitis herpetiformis. Clinical Gastroenterology and Hepatology 2005 3 335-341. (doi:10.1016/S1542-3565(04)00778-5)
17. Fasano A. Celiac disease - how to handle a clinical chameleon. New England Journal of Medicine 2003 348 2568-2570. (doi:10.1056/NEJMe030050)
18. Jayashree B, Bibin YS, Prabhu D, Shanthirani C.S., Gokulakrishnan K., Lakshmi BS, Mohan V & Balasubramanyam M. Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Molecular and Cellular Biochemistry 2014 388 203-210. (doi:10.1007/s11010-013-1911-4)
19. Moreno-Navarrete J.M., Sabater M, Ortega F., Ricart W & Fernandez-Real JM. Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance. PLoS ONE 2012 7 e37160. (doi:10.1371/journal.pone.0037160)
20. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 2004 81 19-25. (doi:10.1016/j.fertnstert.2003.10.004)
21. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004 363 157-163. (doi:10.1016/S0140-6736(03)15268-3)
22. Amato MC, Giordano C, Galia M., Criscimanna A, Vitabile S, Midiri M., Galluzzo A & AlkaMeSy Study Group. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometa-bolic risk. Diabetes Care 2010 33 920-922. (doi:10.2337/dc09-1825)
23. Matthews DR, Hosker JP, Rudenski A.S., Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419. (doi:10.1007/BF00280883)
24. Matsuda M & DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999 22 1462-1470. (doi:10.2337/diacare.22.9. 1462)
25. Goodarzi MO & Korenman SG. The importance of insulin resistance in polycystic ovary syndrome. Fertility and Sterility 2003 80 255-258. (doi:10.1016/S0015-0282(03)00734-9)
26. Shoelson SE, Lee J & Goldfine AB. Inflammation and insulin resistance. Journal of Clinical Investigation 2006 116 1793-1801. (doi:10.1172/JCI29069)
27. Brock M, Trenkmann M, Gay R.E., Gay S., Speich R & Huber LC. MicroRNA-18a enhances the interleukin-6-mediated production of the acute-phase proteins fibrinogen and haptoglobin in human hepatocytes. Journal of Biological Chemistry 2011 286 40142-40150. (doi:10.1074/jbc.M111.251793)
28. Amato MC, Verghi M, Galluzzo A & Giordano C. The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. Human Reproduction 2011 26 1486-1494. (doi:10.1093/humrep/der088)
29. Ma X, Hua J & Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. Journal of Hepatology 2008 49 821-830. (doi:10.1016/j.jhep.2008.05.025)
30. Everard A, Lazarevic V, Derrien M., Girard M, Muccioli GG, Neyrinck A.M., Possemiers S., Van Holle A, Francois P, de Vos WM et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 2011 60 2775-2786. (doi:10.2337/db11-0227)
31. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A., Escobar-Morreale HF, Futterweit W, Lobo R., Norman RJ, Talbott E & Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. Journal of Clinical Endocrinology and Metabolism 2010 95 2038-2049. (doi:10.1210/jc.2009-2724)
32. Burghen GA, Givens JR & Kitabchi AE. Correlation of hyperandro-genism with hyperinsulinism in polycystic ovarian disease. Journal of Clinical Endocrinology and Metabolism 1980 50 113-116. (doi:10.1210/jcem-50-1-113)
33. Diamanti-Kandarakis E & Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews 2012 33 981-1030. (doi:10.1210/er.2011-1034)
34. Alvarez-Blasco F., Botella-Carretero JI, San Millan JL & Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Archives of Internal Medicine 2006 166 2081-2086. (doi:10.1001/archinte.166.19.2081)
35. Bhasin S, Zhang A, Coviello A., Jasuja R, Ulloor J, Singh R., Vesper H & Vasan RS. The impact of assay quality and reference ranges on clinical decision making in the diagnosis of androgen disorders. Steroids 2008 73 1311-1317. (doi:10.1016/j.steroids.2008.07.003)
36. Rosner W, Vesper H & Endocrine Society, American Association for Clinical Chemistry, American Association of Clinical Endocrinologists, Androgen Excess/PCOS Society, American Society for Bone and Mineral Research, American Society for Reproductive Medicine, American Urological Association, Association of Public Health Laboratories, Endocrine Society, Laboratory Corporation of America, North American Menopause Society, Pediatric Endocrine Society. Toward excellence in testosterone testing: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2010 95 4542-4548. (doi:10.1210/jc.2010-1314)